2008: AGM: Shareholders – asked to reward Parasites 25Aug Preliminary Final Report and Annual Report 25Aug RSV licence assigned to AZ - territories expanded 11Aug Human rhinovirus Phase IIa clinical tiral commences 08Aug Bullsh!t Letter to shareholders 31 Jul LANI Phase II completed - Phase III scheduled 24 Jul Quarterly Royalties from Relenza 21 Jul Announced Cooked Deal as good news 16 Jul Appendix 3B - PARASITES REWARDED
2007: 09Aug Preliminary Final Report 01 Aug Appendix 3B - PARASITES REWARDED 31 Jul Biota raises Relenza claim to A$564 - A$704 million 25 Jul GSK release sales result
2006: 6 Sept: Preliminary Results 30 Aug: Announced Court Trial Dates 25 Aug Announced Relenza EU approval extension 17 Aug: Announced HRV commenced Phase 1b Trial 9 Aug: Appendix 3B – PARASITES REWARDED 8 Aug: Announced $8.5m NIH award 2 Aug: Announced HRV phase 1 a Clinical Trial results 26 Jul: GSK release sales results
2005: 26Aug Preliminary Final Report 23Aug Appendix 3B - PARASITES REWARDED 15Aug Biota Confirms Relenza Stockpiling in Germany 15Aug Appointment of new CFO 11Aug Reported Relenza Stockpiling in Germany 04Aug Appendix 3B – PARASITES REWARDED 27Jul Values Claim against GSK at $308 to $430 million 25Jul Appendix 3B - PARASITES REWARDED 21Jul Date Changed for Damages Filing in GSK Suit
Observations: Coincidences or a peculiar pattern of behavior or Cooked Modus Operandi? In the last 4 years, after GSK had reported the sales results to the day of the BTA results were released, there will be good news and Appendix 3B announcements.
Is 2009 going to be any different? I expect a very good GSK sales report. Then follow by Appendix 3B announcements rewarding Peter Cook as if he single-handedly improved Relenza sales and the company profit, followed by a flurry of Good news?? Maybe LANI, Stockpiling sales; Product development news??
BTA Price at posting:
$1.30 Sentiment: None Disclosure: Not Held